Document, TestimonyAlliance Calls for Increased NIH Appropriations in FY 2014
On March 15, 2013, the Alliance for Aging Research submitted testimony to the House Appropriations, Labor, Health and Human Services, and Education Subcommittee, calling for $32 billion in funding for the National Institutes of Health (NIH) in FY 2014. To justify this increase, the Alliance highlighted important NIH-supported work administered through the National Institute on Aging (NIA) and other of the NIH's 27 Institutes and Centers. Particular attention was paid to advances in understanding the basic biology of aging and its link to chronic disease and the formation of a Geroscience Interest Group (GSIG) comprised of 20 Institutes and Centers to coordinate discussion and action across the NIH on research into the processes of aging that underpin most major age-related disease.
To read the Alliance's testimony, click here.
ReportThe Silver Book: Persistent Pain
February 2013Around 100 million Americans live with persistent pain--more than are affected by diabetes, cancer, and heart disease combined. This latest volume of The Silver Book brings together all of the data on persistent pain, all into one place.
Press ReleaseGrowing Burden of Persistent Pain Calls for More Medical Innovation
February 20, 2013
Related topics: Access to Breakthroughs   Aging Research Cancer Federal Funding Health Medical Innovation Persistent Pain Policy ResearchCynthia Bens, Alliance for Aging Research
Penney Cowan, American Chronic Pain Assoc.
Nicole Grady, American Osteopathic Assoc.
Paul Gileno, US Pain Foundationuspainfoundation@gmail.com, 860-788-6062
Washington, D.C. – Today, the Alliance for Aging Research released a new volume of The Silver Book®: Chronic Disease and Medical Innovation in an Aging Nation. This latest addition to The Silver Book series paints a comprehensive picture of the burden of persistent pain, and the value of innovation that helps reduce that burden. The briefing--held in partnership with the American Chronic Pain Association, the American Osteopathic Association, and the US Pain Foundation--featured a medical expert, a pain patient, and leaders from the partnering organizations.
Alliance in the News, Feature ArticleFollowing Katz at FDA
February 11, 2013 | Steve Usdin, Washington Editor
Related topics: Alzheimer's Disease Drug Development Policy
On February 11, 2013, Steve Usdin, Washington Editor of BioCentury, published an article in BioCentury The Bernstein Report on Business focused on the future of the FDA’s Division of Neurology Products following the expected retirement later this year of the current Division Director, Russell Katz, M.D. Representatives from the biopharmaceutical industry and the patient advocacy community were interviewed for this article, including Daniel Perry, President & CEO of the Alliance for Aging research and Chair of the ACT-AD Coalition. Mr. Perry highlighted ACT-AD’s positive relationship with Dr. Katz and expressed hope that Dr. Katz’s successor will approach the review of therapies for Alzheimer’s disease with similar openness and flexibility.
To read the BioCentury article, click here.
Get Mad ColumnHelping Stop a Devastating Disease: The ACT-AD Coalition Continues its Important Work in Alzheimer's
Related topics: Access to Breakthroughs   Alzheimer's Disease Drug Development Health PolicyAlzheimer's disease is a slow, dehumanizing, and fatal disease that strikes 1 in 8 people over the age of 65. While it's typically thought of as a disease that affects memory, it goes well beyond memory loss and eventually leads to death.